Zydus Lifesciences subsidiary has partnered with Zhuhai Beihai Biotech to market a cancer drug, Beizray (Albumin Solubilized ...

Delcath Systems, Inc. ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an update to the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

The Elekta Unity MR-LINAC system combines MRI imaging with radiation therapy to target cancerous cells with pinpoint ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Under the terms of this agreement, Beihai Biotech will be responsible for the manufacturing and supply of the product. Zydus ...

Hair loss can be traumatic and, unfortunately, extremely common. But a New Jersey doctor says he has a new treatment.